Direct survey-weighted rates were correlated with model-predicted rates in 43 counties (Pearson r = 0.32). 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Summary statistics were obtained for sociodemographic and chronic diseases by using cross-tabulation analysis and comparing the county respondents with proportion tests. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ADI was positively associated with blood pressure and cardiometabolic index (CMI), and negatively associated with global and Preclinical Alzheimer's Cognitive Composite (PACC5) scores, in cognitively unimpaired (CU) individuals. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The IVW analysis indicated that antithrombotic agents (odds ratio [OR] = 2.12, 95% confidence interval [CI] = 1.03-4.34, p = 0.04), HMG CoA reductase inhibitors (OR = 1.36, 95% CI = 1.07-1.72, p = 0.01), and salicylic acid and derivatives (OR = 2.77, 95% CI = 1.44-5.32, p = 0.002) are a strong risk factor for dementia with Lewy bodies (DLB); diuretics (OR = 1.13, 95% CI = 1-1.27, p = 0.047) and calcium channel blockers (OR = 1.16, 95% CI = 1.04-1.29, p = 0.007) might be a risk factor for vascular dementia; thyroid preparations (OR = 1.03, 95% CI = 1.01-1.06, p = 0.01), diuretics (OR = 1.06, 95% CI = 1.02-1.11, p = 0.004), and immunosuppressants (OR = 1.07, 95% CI = 1.01-1.12, p = 0.001), are a risk factor for frontotemporal dementia; HMG CoA reductase inhibitors is a risk factor for dementia in Alzheimer disease (OR = 1.32, 95% CI = 1.05-1.65, p = 0.01). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
CD28 molecule expression on the surface of T cells plays a critical role in upregulation of various cytokines synthesis and T-helper (Th) cell proliferation and differentiation. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
34/100
Recent discoveries indicating that the brain retains its ability to adapt and change throughout life have sparked interest in cognitive training (CT) as a possible means to postpone the development of dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
=3.40; P=.04). Greater cognitive improvements were associated with younger age, higher functional status, and lower baseline cognitive function. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This review will describe the evidence for changing the hospital environment to improve nutrition of older people, with particular emphasis on the role of additional mealtime assistance. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Age-related upregulation in microRNA (miR)-204 and downregulation in long noncoding RNA (lncRNA) nuclear enriched abundant transcript 1 (NEAT1) were observed to disrupt Ephrin-B1 (EFNB1)/EphB2 interactions, leading to reduced cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway activation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study aims to investigate how cognitive impairment and social presence influence goal attainment in an ecological virtual environment. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment (MCI) is the transitional stage between normal cognition and dementia and is associated with arterial stiffness, which may lead to cardiovascular disease. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Current evidence suggests a potential for the Mediterranean diet to prevent cognitive decline, largely supported by observational studies, although randomized controlled trials show mixed results. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Previously, we found that circadian desynchrony was involved in isoflurane-induced cognitive impairment. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is characterized by the loss of atonia during REM sleep, causing dream-enacting behavior. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
32/100
Overall, our findings suggest that greater neighborhood disadvantage may influence select domains of memory, and that one’s self-reported loneliness may influence how this relationship manifests. 4 key findings →
Participants: 136 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results showed that the experimental group had a statistically significant difference of attention (TMT-B) and working memory scores, while the control group had no statistically significant difference for both attention and working memory. 3 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Performance on the shopping task significantly differentiated patients and healthy controls for several variables and, in particular, for total time. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our primary outcome was self‐reported history of cognitive screening (never versus ever had screening). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The StrongerMemory program, a structured intervention involving reading aloud, writing by hand, and completing simple math problems, is designed to stimulate the prefrontal cortex and enhance cognitive functioning. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
During the one-year follow-up, the intervention group showed a significant increase in mean cognitive scores (Addenbrooke's cognitive examination), rising from 73.94 to 82.32 (p < 0.001). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Through systematic instruction and retraining visual and sustained attention, the patient was able to engage meaningfully with a high-tech device to increase functional personal choice when supported by a partner. 2 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Overall health is significantly impacted by where one lives. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
RELEVANCE . With age, people experience a decline in cognitive and physical functions, which increases the risk of falls, loss of independence, and deterioration in quality of life. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
28/100
The evidence for cognitive training in preventing cognitive decline in Alzheimer's disease is varied, with some studies indicating cognitive benefits but showing limited impact on functional outcomes or disease progression. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
28/100
Alzheimer's Disease (AD) is a progressive neurodegenerative condition that gradually impairs cognitive abilities such as memory, attention, and problem-solving, leading to significant challenges in everyday functioning and a decline in quality of life. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →